Alpha-synuclein, the protein that builds up into toxic clumps in Parkinson’s disease, may trigger neurons (nerve cells) to increase…
Articles by Margarida Maia, PhD
Factors such as exposure to environmental toxins and repeated blows to the head — all of which can be reduced…
Alpha-synuclein — the protein that forms toxic clumps in the brains of people with Parkinson’s disease — may travel…
A ceramic blanket, a device being developed by Gladiator Therapeutics to improve blood flow and speed up wound healing,…
Vanqua Bio will initiate clinical development of VQ-101 — a small molecule capable of penetrating the brain — in…
Low-dose fosgonimeton (ATH-1017), an investigational small molecule, may have cognitive benefits for people with Parkinson’s disease-related dementia or dementia…
Phasing out fossil fuels could save an estimated 5.1 million lives each year worldwide by preventing deaths attributed to ambient…
People with Parkinson’s disease who maintain the recommended level of weekly physical activity tend to be those with critical…
Some molecular changes that drive damage to brain cells in Parkinson’s disease take place in skin cells too, a…
A Phase 1/2 clinical trial testing AAV-GAD, an investigational gene therapy being developed by MeiraGTx for Parkinson’s disease,…